Norway's Aker BioMarine acquires Danish biotech firm Krill A/S  

The Norwegian nutraceuticals company has acquired Krill A/S, which has developed a process for extracting medically useful oils from planktonic crustaceans found in Arctic waters
It has been an active week in the Danish biotech sector. Hot on the heels of GlaxoSmithKline's big-money agreement with Genmab, Norwegian nutraceuticals company Aker BioMarine has now produced its cheque book to acquire for an undisclosed sum the Danish biotech firm Krill A/S, which concomitantly has been renamed CardicMed A/S. Aker BioMarine, part of the giant Norwegian industrial group Aker, will be stock exchange listed next year.
While Aker BioMarine is active in the area of harvesting krill – the planktonic crustaceans found in Arctic waters – Krill A/S has developed what is described as a revolutionary process for extracting krill oils from these microscopic marine organisms. The commercially attractive feature of this breakthrough is that the oceans contain vast quantities of krill, and krill oils have medically useful properties. Krill A/S has concluded successful tests of krill oils at a Danish hospital, which assessed their effect in preventing blood clots.
Krill A/S was spun out from the University of Southern Denmark, and was founded by NOVI Innovation and Danish entrepreneur Jesper Breuning-Hansen in 2004. Science Ventures Denmark A/S came on board as an investor and part owner when the company was reorganised this year.
Norway's Aker group employs 55,000 people in 45 countries and generates revenues of NOK 80 bn (USD 13 bn). Aker owns a 76.2% share of Aker BioMarine. The news was reported by

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×